Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
WALTHAM, Mass., May 10, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it will host an Analyst Day for the investment community on Wednesday, May 24, 2017 from 8:30 a.m. to 12:00 p.m. Eastern Time. Members of AMAG’s management team and industry experts will provide updates on the Company’s pipeline and commercial programs. In-person attendance requires advanced registration. Please email [email protected] for further information.
A live webcast of the event will be accessible through the Investors section of the company’s website at www.amagpharma.com. A replay of the webcast will also be available and archived on the site.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women's health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. and CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
